[contact-form-7 id="15592" title="Tell me more"]

Contact Next Edge Capital

1 Toronto Street, Suite 200
Toronto, ON M5C 2V6

Telephone: 416.775.3600
Toll-free: 1.877.860.1080
Fax: 416.775.3601
Email: info@nextedgecapital.com

Sign Up

Join our Distribution List
 

Next Edge Biotech and Life Sciences Opportunities Fund

Next Edge Biotech and Life Sciences Opportunities Fund


Profile
Commentary
Presentation

PERFORMANCE

This is a new Fund with an inception date of November 3, 2020 and a trading start date of December 21, 2020. As such, only monthly performance returns will be shown for the first year.

For period ending December 31, 2020.

HISTORICAL PERFORMANCE

CLASS A¹

4.39%*------
1 MONTH3 MONTHS6 MONTHSYTD1 YEAR3 YEARSSINCE INCEP.
JANFEBMARAPRMAYJUNJULAUGSEPOCTNOVDECYTD
2020-----------4.39%*N/A

CLASS F¹

4.44%*------
1 MONTH3 MONTHS6 MONTHSYTD1 YEAR3 YEARSSINCE INCEP.
JANFEBMARAPRMAYJUNJULAUGSEPOCTNOVDECYTD
2020-----------4.44%*N/A

MONTHLY PERFORMANCE BY CLASS

Class NAV List
CLASSNAVMONTHLY
PERFORMANCE1		FUNDSERV
CODE
A$10.444.39%NEC 216
F$10.444.44%NEC 217
Fund Type
Alternative Mutual Fund
Launch Date
December 2020
Minimum Initial Investment
CAD $5,000
Purchases / Redemptions
Daily
Management Fee
Class A
1% per annum; (1% Servicing Fee payable out of the Management Fee)
Class F
0% per annum
Performance Fees
20% of profits with a high water mark
Valuation Pricing
Daily
Fund Codes
Class A - NEC 216
Class F - NEC 217
1. Next Edge Biotech and Life Sciences Opportunities Fund returns are net of all fees and expenses associated with Class A Units and Class F Units charged from December 21, 2020. Returns for 2020 are unaudited. Therefore, performance statistics containing 2020 figures shown in this material are subject to final confirmation. The historical annualized rates of return for the Next Edge Biotech and Life Sciences Opportunities Fund Class A Units as of December 31, 2020 are 1 yr N/A, 3 yr N/A, 5 yr N/A, 10 yr N/A, and CARR N/A; for Class F Units are 1 yr N/A, 3 yr N/A, 5 yr N/A, 10 yr N/A, and CARR N/A.
2. Part Year
* Part Month start date December 21, 2020 to December 31, 2020.
There are inherent limitations in any comparison between a managed portfolio and a passive index. Each index is unmanaged and does not incur management fees, transaction costs or other expenses associated with a private fund. There are risks inherent in hedge fund investing programs.
Potential investors should note that alternative investments can involve significant risks and the value of an investment may go down as well as up. There is no guarantee of trading performance and past or projected performance is not indicative of future results.
Note to Investment Professionals: The information in the Monthly Report is being provided to current investors in the Fund and is being provided to their registered dealers for informational purposes only.
The Fund is not a trust company and does not carry on business as a trust company and, accordingly, the Fund is not registered under the trust company legislation of any jurisdiction. Units of the Fund are not "deposits" within the meaning of the Canada Deposit Insurance Corporation Act (Canada) are not insured under provisions of that Act or any other legislation.
No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. These securities have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from the registration requirements of those laws.
The information provided herein is for information purposes only and does not constitute a solicitation, public offering, advice or recommendations to buy or sell interests in the Fund, the Portfolio, Units or any other Next Edge Product. Please refer to the Fund"s prospectus for more information on the Fund as any information in this Report is qualified in its entirety by the disclosure therein.
DISCLAIMER
The "Next Edge Biotech and Life Sciences Opportunities Fund" or "Fund" means the "Next Edge Biotech and Life Sciences Opportunities Fund". Capitalized terms not defined in this presentation are defined as set forth in the prospectus of the Fund (the "Prospectus"). This communication is not, and under no circumstances is to be construed as, an invitation to make an investment in the Fund nor does it constitute a public offering to sell the Fund or any other products described herein. Applications for the Fund will only be considered on the terms of the Prospectus. Each purchaser of the units (the "Units") may have statutory or contractual rights of action under certain circumstances as disclosed in the Prospectus. Please review the provisions of the applicable securities legislation for particulars of these rights.
Terms defined herein shall have the same meaning as in the Prospectus. Potential investors should note that alternative investments can involve significant risks and the value of an investment may go down as well as up. There is no guarantee of trading performance and past or projected performance is not indicative of future results. Investors should review the Prospectus in its entirety for a complete description of the Fund, its risks, and consult their registered dealers before making an investment.
The information contained in this material is subject to change without notice and Next Edge Capital Corp. will not be held liable for any inaccuracies or misprints. The Fund has not been and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States. The Fund may not be offered or sold in the United States or to US persons.
Any descriptions or information involving investment process or strategies is provided for illustration purposes only, may not be fully indicative of any present or future investments, may be changed at the discretion of the Portfolio Manager and are not intended to reflect performance. The following does not purport to be a complete summary of all of the risks associated with an investment in the Fund. Please see the Fund"s Prospectus for a complete listing and description of the risks associated with an investment in the Fund. The Fund is generally exposed to the following risks: Biotechnology Industry Risk; Borrowing Risk; Counterparty Risk; Credit Risk; Cybersecurity Risk; Derivatives Risk; Equity Securities Risk; ETF Risk; Foreign Currency Risk; Foreign Securities Risk; Interest Rate Risk; Legislation and Litigation Risk; Leverage Risk; Liquidity Risk; Multiple Class Risk; Options Risk; Price Volatility Risk; Repurchase and Reverse Repurchase Transactions and Securities Lending Risk; Short Selling Risk; Stock Market Risk; Substantial Securityholder Risk and Tax Risk.